Myofibroblastic stromal reaction and expression of tenascin-C and laminin in prostate adenocarcinoma

Prostate Cancer and Prostatic Diseases

Volumn 9, Issue 4, 2006, Pages 414-419

  Tomas, D ^a   Ulamec, M ^a   Hudolin, T ^b   Bulimbasic S ^c   Belicza, M ^a   Kruslin B ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c University Hospital Sveti Duh   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

LAMININ; TENASCIN;

ADULT; AGED; ARTICLE; CANCER CELL; CONTROLLED STUDY; DIAGNOSTIC VALUE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYOFIBROBLAST; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; STATISTICAL ANALYSIS; STROMA;

ACTINS; ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DESMIN; HUMANS; IMMUNOHISTOCHEMISTRY; LAMININ; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, MUSCLE TISSUE; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; STROMAL CELLS; TENASCIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 33751583663     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500874     Document Type: Article

References (40)

1. Hayward SW, Cunha GR, Dahiya R. Normal development and carcinogenesis of the prostate. A unifying hypothesis. Ann NY Acad Sc 1996; 784: 50-62.
2. Tomas D, Kruslin B. The potential value of (myo)fibroblastic stromal reaction in the diagnosis of prostatic adenocarcinoma. Prostate 2004; 61: 324-331.
3. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: Introduction of myofibroblast phenotype and extracellular matrix remodeling. Clin Caner Res 2002; 8: 2912-2923.
4. Sappino AP, Schurch W, Gabbiani G. Differentiation repertoire of fibroblastic cells: Expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest 1990; 63: 144-161.
5. Kammerer R, Ehret R, von Kleist S. Isolated extracellular matrixbased three-dimensional in vitro models to study orthotopically cancer cell infiltration and invasion. Eur J Cancer 1998; 34: 1950-1957.
6. Merker HJ. Morphology of the basement membrane. Microsc Res Tech 1994; 28: 95-124.
7. Patarroyo M, Tryggvason K, Virtanen I. Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Cancer Bio 2002; 12: 197-207.
8. Colognato H, Yurchenco PD. Form and function: The laminin family of heterotrimers. Dev Dyn 2000; 218: 213-234.
9. Pupa SM, Menard S, Forti S, Tagliabue E. New insight into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 2002; 192: 259-267.
10. Sounni NE, Noel A. Membrane type-matrix metalloproteinase and tumor progression. Biochimie 2005; 87: 329-342.
11. Chiquet-Ehrismann R. Tenascin and other adhesion-modulating proteins in cancer. Semin Cancer Biol 1993; 4: 301-310.
12. Erickson HP. Tenascin-C, tenascin-R, and tenascin-X: A family of talented proteins in search of their functions. Curr Opin Cell Biol 1993; 5: 869-876.
13. Orend G. Potential oncogenic action of tenascin-C in tumorigenesis. Int J Biochem Cell Biol 2005; 37: 1066-1083.
14. Vollmer G. Biologic and oncologic implications of tenascin-C/ hexabrachion proteins. Crit Rev Oncol/Hematol 1997; 25: 187-210.
15. De Marzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003; 361: 955-964.
16. Martin M, Pujuguet P, Martin F. Role of stromal myofibroblasts infiltrating colon cancer in tumor invasion. Pathol Res Pract 1996; 192: 712-717.
17. Noel A, Foidart JM. The role of stroma in breast carcinoma growth in vivo. J Mammary Gland Biol Neoplasia 1998; 3: 215-225.
18. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348.
19. Rowley DR. What might a stromal response mean to prostate cancer progression? Cancer Metast Rev 1998; 17: 411-419.
20. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol 2001; 166: 2472-2483.
21. Gabbiani G. The myofibroblasts in wound healing and fibrocontractive diseases. J Pathol 2003; 200: 500-503.
22. Wever DO, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003; 200: 429-447.
23. Orimo A, Tomioka Y, Shimizu Y, Sato M, Oigawa S, Kamata K et al. Cancer-associated myofibroblasts possess various factors to promote endometrial tumor progression. Clin Cancer Res 2001; 7: 3097-3105.
24. Orlandini M, Oliveiro S. In fibroblasts VEGF-D expression is induced by cell-cell contact mediated by cadherin-11. J Biol Chem 2001; 276: 6576-6581.
25. Xue Y, Li J, Latijnhouwers MA, Smedts F, Umbas R, Aalders TW et al. Expression of periglandular tenascin-C and basment membrane laminin in normal prostate, benign prostatic hyperplasia and prostate carcinoma. Br J Urol 1998; 81: 844-851.
26. Ibrahim SN, Lightner VA, Ventimiglia JB, Ibrahim GK, Walther PJ, Bigner DD et al. Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma. Hum Pathol 1993; 24: 982-989.
27. Slater MD, Lauer C, Gidley-Baird A, Barden JA. Markers for the development of early prostate cancer. J Pathol 2003; 199: 368-377.
28. Xue Y, Smedts F, Latijnhouwers MA, Ruijter ET, Aalders TW, de la Rosette JJ et al. Tenascin-C expression in prostatic intraepithelial neoplasia (PIN): A marker of prognosis? Anticancer Res 1998; 18: 2679-2684.
29. Bair EL, Chen ML, McDaniel K, Sekiguchi K, Cress AE, Nagle RB et al. Membrane type 1 matrix metalloprotease cleaves laminin-10 and promotes prostate cancer cell migration. Neoplasia 2005; 7: 380-389.
30. Udayakumar TS, Chen ML, Bair EL, Von Bredow DC, Cress AE, Nagle RB et al. Membrane type-1-matrix metalloproteinase expressed by prostate carcinoma cells cleaves human laminin-5 beta3 chain and induces cell migration. Cancer Res 2003; 63: 2292-2299.
31. Koyama S. Coordinate cell-surface expression of matrix metalloproteinases and their inhibitors on cancer-associated myofibroblasts from malignant ascites in patients with gastric carcinoma. J Cancer Res Clin Onco 2005; 23: 1-6.
32. Ottino P, He J, Axelrad TW, Bazan HE. PAF-induced furin and MT1-MMP expression is independent of MMP-2 activation in corneal myofibroblasts. Invest Ophthalmol Vis Sci 2005; 46: 487-496.
33. Yasui H, Andoh A, Bamba S, Inatomi O, Ishida H, Fujiyama Y. Role of fibroblast growth factor-2 in the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human intestinal myofibroblasts. Digestion 2004; 69: 34-44.
34. Hindermann W, Berndt A, Haas KM, Wunderlich H, Katenkamp D, Kosmehl H. Immunohistochemical demonstration of the gamma2 chain of laminin-5 in urinary bladder urothelial carcinoma. Impact for diagnosis and prognosis. Cancer Detect Prev 2003; 27: 109-115.
35. Linder S, Castanos-Velez E, von Rosen A, Biberfeld P. Immunohistochemical expression of extracellular matrix proteins and adhesion molecules in pancreatic carcinoma. Hepatogastroenterology 2001; 48: 1321-1327.
36. Murai S, Umemiya T, Seiki M, Harigaya K. Expression and localization of membrane-type-1 matrix metalloproteinase, CD 44, and laminin-5gamma2 chain during colorectal carcinoma tumor progression. Virchows Arch 2004; 445: 271-278.
37. Brar PK, Dalkin BL, Weyer C, Sallam K, Virtanen I, Nagle RB. Laminin alpha-1, alpha-3, and alpha-5 chain expression in human prepubertal [correction of prepubetal] benign prostate glands and adult benign and malignant prostate glands. Prostate 2003; 55: 65-70.
38. Davis TL, Cress AE, Dalkin BL, Nagle BL. Unique expression pattern of the alpha6beta4 integrin and laminin-5 in human prostate carcinoma. Prostate 2001; 46: 240-248.
39. Hao J, Jackson L, Calaluce C, McDaniel K, Dalkin BL, Nagle RB. Investigation into the mechanism of the loss of laminin 5 (α3β3γ2) expression in prostate cancer. Am J Pathol 2001; 158: 1129-1135.
40. Hao J, Yang Y, McDaniel K, Dalkin BL, Cress AE, Nagle RB. Differential expression of laminin 5 (alpha 3 beta 3 gamma 2) by human malignant and normal prostate. Am J Pathol 1996; 149: 1341-1349.